[Coverage rate and satisfaction of populations after mass treatment with praziquantel and albendazole in Mali].
In Mali, schistosomiasis always remains a major public health problem. In 2005, mass treatment campaigns with praziquantel and albendazole have been organized in all endemic regions. The present study aimed to assess the impact of these mass treatment campaigns and the recipient's satisfaction in two endemic areas (Mopti and Ségou). It was a cross-sectional study with one passage from February to March 2006. The study carried out on political authorities (n=142), teachers and school administers (n=70), health workers (n=46), community distributors (n=33), community members (n=2170) and pupils (n=2480). We used Lot Quality Assurance Sample (LQAS) to determine treatment coverage and recipient's satisfaction. Two types of lots were considered, villages and schools. Questionnaires were used for investigation. In Ségou, the treatment rates varied from 100% at school level and in community in Bla district to 97.2% in the community of Ségou town. In Mopti, a treatment rate of 100% was observed in Bankass and Douentza both at school and in the community. The proportion of happiest individuals (to feel well) after the mass treatment campaign was 72.3% among pupils and 76.6% in the community. The results of this study suggest that the high treatment coverage rates observed during these campaigns should be sustained by a yearly chemotherapy strategy preceded by a community's health education programmes.
Sangho
H
H
Centre de Recherche d’Etude et de Documentation pour la Survie de l’Enfant (CREDOS), BP 2109 Bamako. drsangho@hotmail.com
Dabo
A
A
Sidibé
A
A
Dembélé
R
R
Diawara
A
A
Diallo
A
A
Konaté
S
S
D015766:Albendazole / Q000627:therapeutic use*; D000871:Anthelmintics / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D004358:Drug Therapy / Q000706:statistics & numerical data; D006293:Health Promotion / Q000706:statistics & numerical data; D006801:Humans; D055810:Lot Quality Assurance Sampling; D008302:Mali; D017060:Patient Satisfaction; D011223:Praziquantel / Q000627:therapeutic use*; D012552:Schistosomiasis / Q000188:drug therapy*
D000871:Anthelmintics; D011223:Praziquantel; D015766:Albendazole